These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21654838)

  • 41. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.
    Mukherjee N; Reuland SN; Lu Y; Luo Y; Lambert K; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
    J Invest Dermatol; 2015 Mar; 135(3):842-850. PubMed ID: 25350317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Role of tumor microenvironment in the formation and progression of skin melanoma].
    Olbryt M
    Postepy Hig Med Dosw (Online); 2013 May; 67():413-32. PubMed ID: 23756376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.
    Frank NY; Schatton T; Kim S; Zhan Q; Wilson BJ; Ma J; Saab KR; Osherov V; Widlund HR; Gasser M; Waaga-Gasser AM; Kupper TS; Murphy GF; Frank MH
    Cancer Res; 2011 Feb; 71(4):1474-85. PubMed ID: 21212411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Melanoma: Cellular and vaccinal immunotherapy].
    Dréno B; Khammari A; Knol AC; Labarrière N
    Bull Acad Natl Med; 2014 Feb; 198(2):309-19; discussion 319. PubMed ID: 26263706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Addressing intra-tumoral heterogeneity and therapy resistance.
    Rybinski B; Yun K
    Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell.
    Shakhova O; Sommer L
    Cancer Lett; 2013 Sep; 338(1):74-81. PubMed ID: 23073475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highlights of the 2012 Congress of the Society for Melanoma Research, 8-11 November 2012, Hollywood, CA.
    Vultur A; Webster M; Villanueva J; Herlyn D
    Melanoma Res; 2013 Jun; 23(3):237-40. PubMed ID: 23546222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?
    Menaa F; Houben R; Eyrich M; Broecker EB; Becker JC; Wischhusen J
    G Ital Dermatol Venereol; 2009 Jun; 144(3):287-96. PubMed ID: 19088701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.
    Peretz Y; Wu H; Patel S; Bellacosa A; Katz RA
    PLoS One; 2015; 10(2):e0116839. PubMed ID: 25642713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of Cancer Stem Cell Self-Renewal by HOXB9 Antagonizes Endoplasmic Reticulum Stress-Induced Melanoma Cell Apoptosis via the miR-765-FOXA2 Axis.
    Lin J; Zhang D; Fan Y; Chao Y; Chang J; Li N; Han L; Han C
    J Invest Dermatol; 2018 Jul; 138(7):1609-1619. PubMed ID: 29408459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumoral heterogeneity in neuroblastoma.
    Gomez RL; Ibragimova S; Ramachandran R; Philpott A; Ali FR
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188805. PubMed ID: 36162542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
    Oglesby A; Algazi AP; Daud AI
    Am J Clin Dermatol; 2019 Dec; 20(6):781-796. PubMed ID: 31228012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma.
    Akiyama M; Matsuda Y; Ishiwata T; Naito Z; Kawana S
    J Invest Dermatol; 2013 May; 133(5):1384-7. PubMed ID: 23389394
    [No Abstract]   [Full Text] [Related]  

  • 54. Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression.
    Calvani M; Pelon F; Comito G; Taddei ML; Moretti S; Innocenti S; Nassini R; Gerlini G; Borgognoni L; Bambi F; Giannoni E; Filippi L; Chiarugi P
    Oncotarget; 2015 Mar; 6(7):4615-32. PubMed ID: 25474135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microenvironment and brain tumor stem cell maintenance: impact of the niche.
    Herold-Mende C; Mock A
    Anticancer Agents Med Chem; 2014; 14(8):1065-74. PubMed ID: 25175691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis.
    Song WM; Agrawal P; Von Itter R; Fontanals-Cirera B; Wang M; Zhou X; Mahal LK; Hernando E; Zhang B
    Nat Commun; 2021 Feb; 12(1):1214. PubMed ID: 33619278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment approaches for advanced cutaneous melanoma.
    Stein JA; Brownell I
    J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.
    Schnegg CI; Yang MH; Ghosh SK; Hsu MY
    Cancer Res; 2015 Apr; 75(8):1682-90. PubMed ID: 25769726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Macrophage-tumor cell fusions from peripheral blood of melanoma patients.
    Clawson GA; Matters GL; Xin P; Imamura-Kawasawa Y; Du Z; Thiboutot DM; Helm KF; Neves RI; Abraham T
    PLoS One; 2015; 10(8):e0134320. PubMed ID: 26267609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving cancer stem cells killing in malignant melanoma.
    Bergamaschi D
    Br J Dermatol; 2024 Apr; 190(5):615-616. PubMed ID: 38282338
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.